1.06

7.84% -0.10

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $1.06, with a volume of 1.14M. It is down -7.84% in the last 24 hours and up +25.64% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Previous Close:

$1.16

Open:

$1.14

24h Volume:

1.14M

Relative Volume:

1.11

Market Cap:

$98.59M

Revenue:

$34.48M

Net Income/Loss:

$-102.07M

P/E Ratio:

-0.726

EPS:

-1.46

Net Cash Flow:

$-104.90M

1W Performance:

+4.81%

1M Performance:

+25.64%

6M Performance:

-51.18%

1Y Performance:

-62.49%

1-Day Range:

$1.03

$1.155

1-Week Range:

$1.025

$1.21

52-Week Range:

$0.66

$2.9995

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

147

Twitter

Next Earnings Date

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	1.06	101.84M	34.48M	-102.07M	-104.90M	-1.46
ONC Beone Medicines Ltd Adr	245.60	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.01	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.22	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.80	64.44B	14.09B	4.50B	2.96B	39.28

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

May 29, 2025

Caribou Biosciences, Inc. (NASDAQ:CRBU) Holdings Lowered by Jane Street Group LLC - Defense World

May 29, 2025

Northern Trust Corp Boosts Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World

May 29, 2025

May 28, 2025

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025

May 27, 2025

Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com Nigeria

May 27, 2025

Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com

May 27, 2025

May 23, 2025

Caribou Biosciences (CRBU) Is Paying a $3.9M Settlement to Investors — Here’s How to Get Your Share - TradingView

May 23, 2025

May 22, 2025

Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace

May 22, 2025

May 16, 2025

Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com

May 16, 2025

Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire

May 16, 2025